For this month’s Buyback Wednesdays article, we decided to focus on a company that has had the founder at the helm for over three decades. We wrote about the company in an Insider Weekends post in July 2022 when the CEO purchased shares and then made it a spotlight idea in our August 2022 Special Situations Newsletter. A few weeks ago that company, Medpace Holdings (MEDP), announced a significant buyback of $1 billion (11% of its market cap) alongside reporting strong Q1 results.
Pharmaceutical companies have been increasingly outsourcing non-core functions to focus on key areas like drug discovery and development. By partnering with Contract Research Organizations (CROs) like Medpace, they gain access to specialized expertise needed for clinical trials and regulatory navigation, improving efficiency and reducing R&D costs.